Loading...
 

Volume 35, Issue 1, March 2024



Sign in to download the Issue in PDF format.

Back to the list
Mediterr J Rheumatol 2023;34(1):97-100
Article Links
Large Vessel Vasculitis After the Administration of Oxford-AstraZeneca COVID-19 Vaccine
Olga K. Katsouli1, Vasileios G. Lainis1, Gerasimos G. Kapellos2, Panayiotis G. Vlachoyiannopoulos1
Authors Information

1Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, and Institute for Autoimmune Systemic and Neurologic Diseases, Athens, Greece

2Haematology Department, Athens Medical Centre, Athens, Greece

O Katsouli, VG Lainis, GG Kapellos, PG Vlachoyiannopoulos

Abstract

We report a case of a 52-year-old female with Large Vessel Vasculitis (LVV) after vaccination with Oxford-AstraZeneca COVID-19 vaccine. She was presented with fever, started two weeks after the second dose of vaccine. Laboratory values, revealed elevated inflammatory markers and chronic disease anaemia. All the infectious causes were excluded, and immunology tests were negative. Computed Tomography (CT) demonstrated concentric wall thickening of ascending and descending aorta. Positron Emission Tomography (PET) scan showed increased vascular fluorodeoxyglucose (FDG), compatible with LVV. Within one month of treatment with high dose glucocorticoids and iv cyclophosphamide, laboratory findings normalised, and fever resolved.


Cite this article as: Katsouli OK, Lainis VG, Kapellos GG, Vlachoyiannopoulos PG. Large Vessel Vasculitis After the Administration of Oxford-AstraZeneca COVID-19 Vaccine. Large Vessel Vasculitis After the Administration of Oxford-AstraZeneca COVID-19 Vaccine. Mediterr J Rheumatol 2023;34(1):97-100.

Article Submitted: 20 Dec 2022; Revised Form: 30 Jan 2023; Article Accepted: 05 Feb 2023; Available Online: 31 Mar 2023

https://doi.org/10.31138/mjr.34.1.97

This work is licensed under a Creative Commons Attribution 4.0 International License.

©2023 The Author(s).

Keywords: vasculitis, COVID-19, vaccination
Full Text

INTRODUCTION

The high rate of transmission of the Coronavirus Disease 2019 (COVID-19) and the lack of effective treatment led to a rapid development of vaccines. By the end of 2020, several vaccines were available for use in many countries, over 40 candidate vaccines were under assessment in clinical trials and over 150 undergoing preclinical studies.

To date, the European Medicines Agency (EMA) authorized four COVID-19 vaccines: BNT162b2 vaccine (Pfizer and BioNTech, Comirnaty®), mRNA-1273 vaccine (Moderna Therapeutics, SpikeVax®), ChAdOx1 nCoV-19 (AstraZeneca and Oxford University, Vaxzevria®) and Ad26.COV2.S (Janssen COVID‑19 vaccine, Jcovden®). Although these vaccines are the most powerful weapon against COVID-19 disease and are generally well-tolerated, various adverse events have been observed and reported, including several types of vasculitis.

Herein, we report a case of Large Vessel Vasculitis in a 52-year-old female, 2 weeks after the administration of Oxford-AstraZeneca COVID-19 vaccine (Vaxzevria®).

 

CASE PRESENTATION

A previously healthy 52-years-old female was presented, in our Rheumatology Department, with evening fever, up to 38.2⁰C, accompanied by fatigue, that started 5 months ago. The symptoms began two weeks, after the administration of the second dose of AstraZeneca vaccine. Previously, the patient had visited several doctors, who after a rapid work-up to rule out common infections, gave unsuccessful treatments with non-steroid anti-inflammatory drugs.

On physical examination, she was alert, awake, but she was ill-appearing. Her vital signs were within normal limits and the rest of examination was unremarkable. In particular, there was no tenderness upon palpation of the temporal region, arteries were evenly palpated on all extremities and the auscultation of the subclavian and axillary regions was normal.

Complete blood count showed mild anaemia (haemoglobin 10.3 g/dL) with normal differential, ESR=111 mm/hr (ref. range: < 20 mm/hr), C-reactive protein=104 mg/L (ref. range: 0 to 7 mg/L), ferritin levels 560 ng/mL (ref. range: 24 to 307 ng/mL) and plasma fibrinogen levels 773 mg/d (ref. range: 200 to 400 mg/dL). Blood biochemistry was within normal limits.

Viral hepatitis panel, blood and urine cultures, ELISA test for HIV, Wright test, VDRL, serology for EBV, CMV, Quantiferon-TB and PCR test for SARS-CoV2 were all negative. Furthermore, immunology tests including antinuclear antibodies (ANA), antibodies to extractable nuclear antigens (ENAs), anti-mitochondrial (AMA), anti-phospholipid (aPL), and anti-neutrophil cytoplasmic antibodies (ANCAs) were negative. IgG4 serum levels were also normal.

Heart ultrasound revealed mild pericardial effusion with no evidence of valvular vegetations, intramural thrombi, or solid tumours.Contrast-enhancedComputed Tomography (CT) of thorax/abdomen, demonstrated concentric wall thickening of ascending aorta, aortic arch, and descending aorta. Due to these findings, a Positron Emission Tomography (PET) scan was performed, which showed increased fluorodeoxyglucose (FDG) uptake throughout aortic arch, thoracic and abdominal aorta, subclavian, carotid, and axillary arteries, compatible with LVV (Figure 1, Figure 2). She was diagnosed as LVV related to vaccination.

Figure 1.
 


Figure 2.
 

According to the 2018 update of the EULAR recommendations for the management of LVV,1 we administered to the patient high doses of glucocorticoids (50 mg/day prednisone-equivalent). Due to the extensive vascular damage and the need for approval of tocilizumab administration for LVV treatment by the Hellenic Food and Drug Organization lasting 4 to 8 weeks, the patient was also placed on induction therapy with 6 monthly intravenous pulses of 1g cyclophosphamide, followed by maintenance treatment with subcutaneous tocilizumab 162 mg weekly. The patient did not present any complication during the induction and maintenance treatment. 

Within the first month, fever resolved, and the inflammatory markers normalised. Eight months later, the patient remains asymptomatic, receiving treatment with Tocilizumab 162 mg weekly, while the tapering of glucocorticoids is still ongoing.

 

DISCUSSION

LVV is defined as the inflammation of the aorta and its major branches. The clinical presentation presents a wide range of symptoms, ranging from general symptoms to potentially life-threatening conditions, such as aortic rupture. The symptoms and signs depend on the underlying cause, whereas the non-specific nature of them requires a high index of suspicion by the clinician to make an early diagnosis.2

The aetiological classification of LVV includes various non-infectious and infectious causes. Giant cell arteritis (GCA) and Takayasu’s arteritis are the most common representatives of non-infectious causes, although LVV is also associated with other rheumatic diseases.3

As far as the infectious LVV is concerned, the colonisation of damaged endothelium due to haematogenous dissemination of microbes leads to activation of collagenolytic and elastolytic enzymes, resulting in aneurysm formation within weeks of infection. Among the most prevalent causative pathogens are Streptococcus pyogenes, Streptococcus pneumoniae, Salmonella and Staphylococcus species.3

Vasculitis can be also triggered by some drugs. Several types of vasculitic disorders have been reported after the administration of various vaccines. The dominant responsible vaccine is the influenza vaccine.4 Nowadays, several cases of vasculitis have been described in the literature,5-8 after both COVID-19 disease or SARS-CoV-2 vaccination (Table 1).


Table 1. Cases of vasculitis after SARS-CoV-2 vaccination, which have been described in the literature.
 


Abdelmaksoud et al. reported 40 cases with vasculitis post SARS-CoV2 vaccination, the most common types of them were IgA and Leukocytoclastic vasculitis, while 3 cases of lymphocytic vasculitis, 2 cases of ANCA-associated vasculitis, 3 cases of urticarial vasculitis and 1 case of immune complex vasculitis were also observed. Μost cases occurred about 6.2 days after vaccination with mRNA vaccines, while 12 cases had received the ChAdOx1 nCoV-19 AstraZeneca vaccine.9 Gilio et al. reported a case of LVV in a 63-year-old patient after the first dose of BNT162b2—Pfizer-BioNTech vaccine. The PET scan performed, showed increased vascular fluorodeoxyglucose (FDG) uptake compatible with LVV, with a picture similar to our patient.10

In the period from January 6th, 2021, until August 7th, 2021 the Netherlands Pharmacovigilance Centre Lareb received 68 reports of vasculitic events occurred between 0 and 26 days after the administration of COVID-19 vaccines. The vast majority of cases involved vasculitis limited to the skin, but 11 cases of GCA were also reported.11 Furthermore, on October 27th, 2022, an analysis of all yellow cards with adverse events that occurred after vaccination with AstraZeneca vaccine during the period 4/1/21 to 26/10/22 was published in the UK. The author emphasises that the adverse reactions are not necessarily due to the vaccine, but the reporter suspected that there is a possible causal and temporal association. Sixty-nine cases of GCA and three cases of aortitis, the type of which was not specified, reported in this analysis print.12

The pathophysiologic explanation of the association of LVV with the SARS-CoV-2 vaccine has not been fully established, but is based on the following evidence:  The vaccine induces Toll Like Receptor (TLR) activation,13 which in turn activates the production of IL-6 linked to disease pathogenesis.14 In addition, vaccination-induced antibodies against the spike protein of SARS-CoV-2 cross-react with many human proteins and form immune complexes that disrupt the endothelium.15 Finally, there is evidence that patients carrying the HLA-DRB1 gene are more prone to develop LVV or polymyalgia rheumatica after influenza vaccination, suggesting a coordination of genetic makeup and environmental factors in the induction of vasculitis.16

LVV is treated by corticosteroids and tocilizumab, as both induction and maintenance therapy.1 Regarding the therapeutic option followed in our case, we have to point out that the administration of tocilizumab for LVV needs approval by the Hellenic Food and Drug Administration which takes one to two months. Therefore, we administered cyclophosphamide based on previous reports.17-19

 

CONCLUSION

We report a case of development of a large vessel vasculitis, 2 weeks after the administration of the second dose of ChAdOx1 nCoV-19, Oxford-AstraZeneca vaccine. Interestingly, the patient exhibited an extensive vascular inflammation, involving the aorta and its major branches, without presenting symptoms of vascular damage, but only general symptoms, such as fever. We are convinced that, this case will guide the clinicians to be more aware of this complication, without discouraging the vaccination program, the value of which is indisputable.

 

CONFLICT OF INTEREST

The authors declare no conflict of interest.

References
  1. Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2020 Jan;79(1):19-30.
  2. Jaikaran O, Nicoara M, Hingorani A. Noninfectious aortitis: A case report. Vascular 2020 Oct;28(5):609-11.
  3. Shchetynska-Marinova T, Amendt K, Sadick M, Keese M, Sigl M. Aortitis - An Interdisciplinary Challenge. In Vivo 2021 Jan-Feb;35(1):41-52.
  4. Bonetto C, Trotta F, Felicetti P, Alarcón GS, Santuccio C, Bachtiar NS, et al. Brighton Collaboration Vasculitis Working Group. Vasculitis as an adverse event following immunization - Systematic literature review. Vaccine 2016 Dec 12;34(51):6641-51.
  5. Oda R, Inagaki T, Ishikane M, Hotta M, Shimomura A, Sato M, et al. Case of adult large vessel vasculitis after SARS-CoV-2 infection. Ann Rheum Dis 2023 Jan;82(1):e25.
  6. Kim Y, Kang J, Lee SG, Kim GT. COVID-19 vaccination-related small vessel vasculitis with multiorgan involvement. Z Rheumatol 2022;81:509-12.
  7. Corrà A, Verdelli A, Mariotti EB, Ruffo di Calabria V, Quintarelli L, Aimo C, et al. Cutaneous vasculitis: Lessons from COVID-19 and COVID-19 vaccination. Front Med. 9:1013846.
  8. Tesch F, Ehm F, Vivirito A, Wende D, Batram M, Loser F, et al. Incident autoimmune diseases in association with a SARS-CoV-2 infection: A matched cohort study. https://doi.org/10.1101/2023.01.25.23285014
  9. Abdelmaksoud A, Wollina U, Temiz SA, Hasan A. SARS-CoV-2 vaccination-induced cutaneous vasculitis: Report of two new cases and literature review. Dermatol Ther 2022 Jun;35(6):e15458.
  10. Gilio M, De Stefano G. Large vessel vasculitis following the Pfizer BioNTech COVID 19 vaccine. Intern Emerg Med 2022; 17(4): 1239-41.
  11. Vasculitis and administration of COVID-19 vaccines. Netherlands Pharmacovigilance Centre Lareb. https://www.lareb.nl/media/x30nhooz/signal_2021_vasculitis-and-administration-of-covid-19-vaccines_gws.pdf
  12. COVID-19 vaccine AstraZeneca analysis print. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1115342/COVID-19_Vaccine_AstraZeneca_analysis_print_-_26OCT22.pdf
  13. Teijaro JR, Farber DL. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol 2021; 21(4):195-7.
  14. Harky A, Fok M, Balmforth D, Bashir M. Pathogenesis of large vessel vasculitis: Implications for disease classification and future therapies. Vasc Med 2019 Feb;24(1):79-88.
  15. Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev 2021 Apr;20(4):102792.
  16. Liozon E, Parreau S, Filloux M, Dumonteil S, Gondran G, Bezanahary H, et al. Giant cell arteritis or polymyalgia rheumatica after influenza vaccination: A study of 12 patients and a literature review. Autoimmun Rev 2021 Feb;20(2):102732.
  17. Quartuccio L, Maset M, De Maglio G, Pontarini E, Fabris M, Mansutti E, et al. Role of oral cyclophosphamide in the treatment of giant cell arteritis. Rheumatology 2012 Sep;51(9):1677-86.
  18. de Boysson H, Boutemy J, Creveuil C, Ollivier Y, Letellier P, Pagnoux C,  et al. Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review. Semin Arthritis Rheum 2013 Aug;43(1):105-12.
  19. Henes JC, Mueller M, Pfannenberg C, Kanz L, Kötter I. Cyclophosphamide for large vessel vasculitis: assessment of response by PET/CT. Clin Exp Rheumatol 2011 Jan-Feb;29(1 Suppl 64):S43-8.